About RedPath IP
RedPath IP is a Healthcare company based in Pittsburgh (United States) founded in 2004, and was acquired by PDI in November 2014. It operates as a risk of cancer progression is assessed via the PathFinder platform. RedPath IP has raised $8.71 million across 4 funding rounds from investors including PH PDI, Inflexion Partners and NewSpring Capital. The company has 153 employees. RedPath IP offers products and services including ThyGenNEXT, ThyraMIR v2, RespriDX, and BarreGen. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its legal entity is PDI, INC. Its competitors include Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
The company was founded in 2004 and is based in Pittsburgh, United States, within the healthcare sector focused on oncology. Operations involve evaluating the likelihood of cancer metastasis through the proprietary PathFinder platform. Patients are stratified according to risk levels, which helps reduce the need for repeated diagnostic testing and associated costs. Services are provided to support clinical decision-making in cancer management.
- Headquarters Pittsburgh, United States
- Employees 153
- Stage Acquired
- SectorsHealthcare
- Website redpathip.com
- Social LinkedIn X
- Acquired by PDI (Nov 2014)
- Legal Name Pdi, Inc.
Products & Services of RedPath IP
RedPath IP offers a comprehensive portfolio of products and services, including ThyGenNEXT, ThyraMIR v2, RespriDX, and BarreGen.
Oncogenic mutation panel to identify malignant thyroid nodules.
MicroRNA assay for classifying cancer risk in thyroid nodules.
Molecular test to differentiate lung cancer types and origins.
Risk classifier for progression from Barrett's Esophagus to cancer.
Funding Insights of RedPath IP
RedPath IP has successfully raised a total of $8.71M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $612.5 thousand completed in April 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.71M
- Total Rounds 4
- Last Round Series A — $612,500
- First Round $6.5M
(Dec 2006)
- Investors Count 4
All 4 funding rounds of RedPath IP with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2013 | $612,500 | Series A | – | – | – |
| Aug 2012 | $588,218 | Debt – Conventional | – | – | – |
| Mar 2011 | $1.6M | Series A | – | – | – |
| Dec 2006 | $6.5M | Series A | – | – |
5 investors in total: 5 institutional.
Investors in RedPath IP
RedPath IP has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include PH PDI, Inflexion Partners and NewSpring Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | inflexionvc.com | - | |
Investment firm focusing on lower-middle market growth, healthcare, and various strategies. | – | newspringcapital.com | - | |
CID Capital is engaged in lower-middle-market buyout investments. | 1981 | cidcap.com | Carmel, United States | |
Seneca Partners is recognized as a leading independent sponsor in North America. | – | senecapartners.com | Detroit, United States | |
Healthcare consulting and clinical outsourced solutions are provided by PDI. | 1988 | ph-pdi.com | Hamilton, United States |
Investor details for RedPath IP
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of RedPath IP
4 dated milestones of RedPath IP across 10 years, from founding to its latest funding, stage changes and deals.
- Founded RedPath IP is founded.
- Funding First funding round of $6.5M.
- Funding Latest funding round, Series A, of $612K.
- Exit Acquired by PDI.
Competitors of RedPath IP
RedPath IP has 9 listed competitors in our database, 8 of them funded. They include Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| prenetics.com | 2009 | Hong Kong, China | $67.65M | – | Health risks are identified through online genetic and diagnostic testing. | |
| veracyte.com | 2008 | San Francisco, United States | $67.9M | 815 | Genomics-based diagnostic tests for cancer are developed. | |
| thrivedetect.com | 2019 | Cambridge, United States | $367M | 138 | Blood-based liquid biopsy tests for multiple cancer detection are provided. | |
| delfidiagnostics.com | 2019 | Baltimore, United States | $331.59M | – | Provider of DNA sequencing for cancer detection | |
| exactsciences.com | 1995 | Madison, United States | – | 6,600 | Non-invasive molecular diagnostic tests for cancer detection are provided. |
Detailed competitors of RedPath IP
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
10 companies that operate in the same segment as RedPath IP (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about RedPath IP
RedPath IP was founded in 2004 and raised its 1st funding round 2 years after it was founded.
RedPath IP is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
RedPath IP is a funded company, having raised a total of $8.71M across 4 funding rounds to date. The company's 1st funding round was a Series A of $6.5M, raised on Dec 2006.
RedPath IP has 153 employees.
The company was founded in 2004 and is based in Pittsburgh, United States, within the healthcare sector focused on oncology. Operations involve evaluating the likelihood of cancer metastasis through the proprietary PathFinder platform. Patients are stratified according to risk levels, which helps reduce the need for repeated diagnostic testing and associated costs. Services are provided to support clinical decision-making in cancer management.
RedPath IP's top competitors include Guardant Health, Exact Sciences and Foundation Medicine.
RedPath IP offers ThyGenNEXT, ThyraMIR v2, RespriDX, and BarreGen.
RedPath IP has 5 investors. Key investors include PH PDI, Inflexion Partners, NewSpring Capital, CID Capital, and Seneca Partners.
RedPath IP operates through Pdi, Inc..
Yes. RedPath IP was acquired by PDI in November 2014.